Comparative Pharmacology
Head-to-head clinical analysis: LEVORA 0 15 30 21 versus TRI SPRINTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVORA 0 15 30 21 versus TRI SPRINTEC.
LEVORA 0.15/30-21 vs TRI-SPRINTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; levonorgestrel inhibits ovulation and thickens cervical mucus, impairing sperm penetration. Also induces endometrial atrophy.
Combination of ethinyl estradiol and norgestimate suppresses gonadotropin release, inhibiting ovulation, and increases viscosity of cervical mucus to inhibit sperm penetration.
One tablet orally once daily for 21 days, followed by 7 tablet-free days.
One tablet (0.035 mg ethinyl estradiol / 0.250 mg norgestimate) orally once daily for 21 days, followed by 7 days of placebo tablets. Repeat cycle.
None Documented
None Documented
20-30 hours for ethinyl estradiol; 2-4 hours for levonorgestrel. Steady-state reached in 5-7 days
Norelgestromin: 28 hours; Ethinyl estradiol: 17 hours. Steady-state achieved within 7 days.
Urine (50-60% as metabolites), feces (30-40% as glucuronides); <10% unchanged
Renal: 50% (metabolites); Fecal: 35% (eliminated in bile); unchanged drug <1%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive